- Cornerstone Therapeutics (CRTX +4.2%) moves higher on a solid Q2, reporting earnings of $0.19 per share and beating consensus estimates of $0.12.
- Revenues were $40.4M, up 88% Y/Y and above the analyst estimate of $35.79M. In the same period last year, the company reported $0.17 loss per share on revenues of $21.5M.
- Gross margin of 75%, compared to 59% in Q212, primarily due to the addition of CARDENE I.V., as well as growth in net product sales resulting from price increases and lower estimated rates for certain sales allowances.
Cornerstone Therapeutics gains on Q2 earnings beat
Aug 6 2013, 15:35 ET